anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

General: This product is to be used as directed by a physician and should not be used to treat any condition other than that for which it was prescribed. If redness or irritation occurs, discontinue use and consult a physician. 

Information for Patients: Patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. Avoid contact with eyes, lips and mucous membranes. 

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed. 

Pregnancy:Category C. Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. 

  
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.
A tumor weak acid microenvironment-sensitive aptamer triptolide conjugate. A 14-position hydroxyl group of triptolide is coupled with an aptamer by means of an acetal ester linking bond. The linking bond is an acid-sensitive linking bond. The cleavage condition of the linking bond is that the pH value ranges from 3.5 to 6.5, and the linking bond is easier to cleave in a tumor microenvironment. On the basis of the characteristic that the aptamer targets high expression protein on the surface of a tumor cell membrane, the conjugate delivers triptolide to tumor cells in a targeted mode and mediates endocytosis to a lysosome. On the basis of the characteristic of the lysosome acid environment, the acetal ester linking bond releases complete triptolide in the lysosome acid environment, and targeted killing is carried on the tumor cells. The defect in the prior art that the cancer cell inhibition effect is not obvious due to the fact that the linking bond in the aptamer triptolide conjugate is low in acid sensitivity, and not prone to cleavage in the in-vivo cancer cell environment, and directional release amount of triptolide is insufficient is overcome.
The invention belongs to the field of biological pesticides, and discloses a sugarcane endogenous bacillus amyloliquefaciens CGB15 strain and application thereof. The bacillus amyloliquefaciens CGB15 strain is preserved in Guangdong province microorganism strain preservation center in 2019, 10 and 17, and the preservation number is GDMCC No:60742 the storage address is: guangzhou city, first furious Zhonglu No. 100 large yard No. 59 building No. 5. The bacillus amyloliquefaciens CGB15 strain has strong inhibiting effect on sugarcane smut, rice blast, litchi fujiensis, litchi colletotrichum and banana fusarium wilt, and has excellent biological control effect. The microbial preparation obtained by the strain has simple preparation and use methods, broad-spectrum disease resistance, small influence on the ecological environment, no influence on the quality of crops and excellent application prospect.
PURPOSE:To obtain a blood cell-increasing agent having little side effect and activity extremely increasing a number of blood cells, e.g. platelet and erythrocyte, excellent in life lengthening effect and useful e.g. for radiotherapy of cancer by compounding ursolic acid (salt) as an active component. CONSTITUTION:This blood cell-increasing agent contains ursolic acid (salt) of formula as an active component. Further, the daily dose of the active component is preferably in the range of 1-1000mg for an adult. The active component is obtained by extracting e.g. fruits of Uvae ursi folium, etc., with an organic solvent, e.g. ethanol.
Primary tracheal schwannomas are rare benign tumours. This is a case report, and therefore, no specific methods or results are applicable. We here report a case of a tracheal schwannoma in an early adolescent girl presenting with subcutaneous emphysema and symptoms of airway obstruction. Tracheal resection and reconstruction by primary anastomosis were performed. Pathology confirmed the diagnosis of tracheal schwannoma. This is an unusual life-threatening presentation of a benign rare tracheal tumour with a challenging approach to management.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use excellent in UV ray- protecting action, low stimulative, good in usability and expressing high skin- improving effects by containing a highly hydrophilic benzophenone derivative and a humectant. SOLUTION: This skin preparation for external use contains a benzophenone derivative of the formula [R1 and R2 are each H, OH or a 1-4C alkoxy; R3 to R6 are each H or a 1-2C alkyl, one or more of R3 to R6 are each an alkyl; A is a sugar residue having no protecting group; (n) is 1 or 2] and a humectant(e.g. propylene glycol, 1, 3-butylene glycol) as effective ingredients. The compound of the formula is excellent in chemical stability and oxidative stability, soluble in water, has absorption bands in the UV region, is capable of retaining moisture and is nonionic, thus can be blended without depending on pH of a system and does not destroy the state of the system. The compound can be blended with cosmetic materials, medicines, etc., as it is good in solubility to various humectants. As the compound of the formula, 2-hydroxy-4-(2- glycosyloxy-2-methylethoxy) benzophenone is cited.
Myocardial remodelling, entailing cellular and molecular changes in the different components of the cardiac tissue in response to damage, underlies the morphological and structural changes leading to cardiac remodelling, which in turn contributes to cardiac dysfunction and disease progression. Since cardiac tissue is not available for histomolecular diagnosis, surrogate markers are needed for evaluating myocardial remodelling as part of the clinical management of patients with cardiac disease. In this setting, circulating biomarkers, a component of the liquid biopsy, provide a promising approach for the fast, affordable and scalable screening of large numbers of patients, allowing the detection of different pathological features related to myocardial remodelling, aiding in risk stratification and therapy monitoring. However, despite the advances in the field and the identification of numerous potential candidates, their implementation in clinical practice beyond natriuretic peptides and troponins is mostly lacking. In this review, we will discuss some biomarkers related to alterations in the main cardiac tissue compartments (cardiomyocytes, extracellular matrix, endothelium and immune cells) which have shown potential for the assessment of cardiovascular risk, cardiac remodelling and therapy effects. The hurdles and challenges for their translation into clinical practice will also be addressed.
This systematic review and meta-analysis investigated the impact of salvage surgery on 5-year overall survival (OS) and prognostic factors in recurrent oral cavity cancer (rOCC) patients. Relevant literature before May 2022 was reviewed, including retrospective cohort studies and observational studies comparing salvage surgery to other treatments. Risk-of-bias assessments were conducted using the Newcastle-Ottawa scale. Statistical and subgroup analyses assessed the impact of salvage surgery on 5-year OS and prognostic factors. 3036 documents were initially retrieved, with 14 retrospective cohort studies (2069 participants) included. Meta-analysis of 5-year OS in salvage surgery patients yielded a rate of 43.0%. Subgroup analysis showed higher OS in Asians (49.9% vs. 36.9%, p = 0.003) and late-relapse (63.8% vs. 30.0%, p = 0.004) groups. Prognostic factors revealed hazards associated with nodal recurrence, extranodal extension, and perineural invasion. Salvage surgery is a viable option for rOCC patients, showing favorable 5-year OS outcomes. Low publication bias enhances study reliability, but its single-arm design limits conclusions on salvage surgery superiority over other treatments.
Systems and methods for monitoring a patient are provided for improving reactions to patient events, auditing, accountability, training tools, hospital compliance, and pharmaceutical compliance, among other things. In an embodiment, a system may include a user device, a server, and a database. Based on a user input by a healthcare practitioner (e.g., the patient's condition, logging the administration of medication to the patient, etc.), a treatment plan may be generated or retrieved from memory (e.g., the database). The treatment plan may, for example, be a schedule that indicates a timing in which the patient must be monitored during the administration of the medication (e.g., where the medication is administered over a 24 hour period) or after the administration of the medication. If the healthcare practitioner completes tasks in accordance with the schedule, the tasks may be logged into memory. If the healthcare practitioner fails to complete tasks in accordance with the schedule, the failure may be logged into memory, communicated to one or more user devices, communicated to an administrator device, and/or communicated to a server that may revise the schedule or generate a new treatment plan.
Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
The study will involve a randomized crossover trial of two medications: amlodipine besylate 10mg and chlorthalidone 25mg daily by mouth. Amlodipine was selected as the dihydropyridine calcium channel blocker (CCB) due to extensive trial evidence demonstrating its efficacy in hypertension (HTN) in the general population and established safety and efficacy for calcineurin inhibitor (CNI)-induce HTN in kidney transplant recipients. Chlorthalidone was chosen amongst other thiazides due to its favorable safety profile, superior effectiveness in reducing cardiovascular events (CVEs) in the general population, stronger reduction in central pressure, and prior evidence of efficacy in kidney transplant recipients with CNI-induced HTN. Dosing for either medication was determined based on the median and maximum recommended doses for each medication when used for the treatment of stage II HTN BP ≥140/≥90 and previous trial evidence demonstrating similar blood pressure-lowering effects of amlodipine and chlorthalidone at these doses. We recognize that several prior studies have used a starting dose of chlorthalidone 12.5mg; however, this dose is no longer available in the U.S. and tablets are not scored to allow for accurate trial dosing. We specifically selected a relatively short duration of follow up (six weeks per intervention) due to several factors, including 1) the time to peak hemodynamic effects and durations of action of the trial interventions, balanced with 2) optimizing adherence to the study protocols to be able to measure key mechanistic factors, and 3) minimizing dropout. Given the well-described half-life elimination of the two medications, we do not anticipate issues with crossover effects in the second phase outcome assessments occurring six weeks following the washout period. Nonetheless, exploratory analyses will account for potential period or crossover effects using mixed effects models.
The treatment cohort which consists of patients who have experienced an acute ischemic stroke will participate in 1 study visit. They will undergo 1 function MRI before, during and after a NeuroGlove session.
UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
Cervical cancer is a preventable disease. Nevertheless, stagnation has been seen in incidence rates also in countries with well-functioning healthcare. On this basis, we investigated associations between control interventions and changes in cervical cancer incidence in Denmark from 2009 to 2022. Data on human papillomavirus (HPV)-vaccination were retrieved from Staten's Serum Institute; on screening recommendations from Danish Health Authority, on screening performance from Danish Quality Database for Cervical Screening; and on cervical cancer incidence from Nordcan and Danish Cancer Register. We reported coverage with HPV vaccination (1+ dose); coverage with cervical cell samples; number of women with primary HPV tests; proportion of non-normal cell samples without timely follow-up; number of conizations; and cervical cancer incidence rates. In 2022, all women aged ≤29 had been offered childhood HPV vaccination with coverage of 80%-90%. By 2020-2022, the cervical cancer incidence rate in women aged 20-29 was 3 per 100,000; at level of disease elimination. In 2017, women aged 70+ were offered a one-time HPV screening, and by 2020-2022, the old-age peak in cervical cancer incidence had largely disappeared. From 2009 to 2022, proportion of non-normal cell samples without timely follow-up decreased from 20% to 10%, and conventional cytology was largely replaced by SurePath liquid-based cytology; these factors could explain the steady decrease in cervical cancer incidence rate. Implementation of primary HPV screening in women aged 30-59 in 2021 was reflected in a, probably temporary, increase in the 2022 cervical cancer incidence rate. In conclusion, combined interventions with childhood HPV vaccination; one-time HPV screening of elderly women; and better management of screening broke previous stagnation in cervical cancer incidence rate.
Provided are a composition for diagnosing vascular disease including an agent measuring a level of interleukin 12 receptor beta 2 protein in the blood, and a kit for diagnosing vascular disease including the same. Further, provided is a method of providing information for diagnosing vascular disease, the method including the step of measuring a level of interleukin 12 receptor beta 2 protein in a blood sample separated from an individual suspected of having vascular disease. Furthermore, provided are a composition for preventing or treating vascular disease including an interleukin 12 receptor beta 2 activity inhibitor, and a method of screening a therapeutic agent for vascular disease, the method including the step of treating smooth muscle cells with a test agent for vascular disease treatment and measuring an expression level of interleukin 12 receptor beta 2. According to the present invention, when interleukin 12 receptor beta 2 is used as a biomarker for vascular disease, in particular, myocardial infarction or unstable angina, vascular disease, of which diagnosis has been performed only by angiography, can be diagnosed using blood in a rapid non-invasive economic manner. Accordingly, the early diagnosis of vascular disease is possible, since the disease has been diagnosed based on subjective symptoms after the appearance of ischemic symptoms with development of the disease. The promise of early diagnosis, prevention and treatment is realized.
Heart attacks, also known as myocardial infarctions (MIs), are one of the main reasons people die from cardiovascular diseases (CVDs) worldwide. Neferine, an alkaloid derived from Nelumbo nucifera seeds, has garnered interest due to its purported medicinal effects. In the current research, we induced MI in rats using the β-adrenergic agonist isoproterenol to investigate whether neferine can improve cardiac dysfunction. The rats were separated into four groups: control, isoproterenol (ISO), and two treatment groups received neferine at doses of 10 or 20 mg/kg once daily for 28 days. On days 27 and 28, the groups undergoing treatment were administered with an ISO injection. Results showed that pretreatment with neferine strongly protected against changes in lipid profiles and cardiac functional markers in ISO-administered rats. Neferine attenuated histopathologic changes, collagen deposition, and myocardial fibrosis in rats administered ISO. Neferine pretreatment significantly inhibited the oxidative stress, inflammatory, and apoptotic markers in the heart of ISO-injected rats. This was achieved through Nrf2/Keap1/ARE signaling stimulation, TLR4/NF-κB/MAPK-mediated signaling inhibition, and activation of the intrinsic apoptotic pathway. Using CB-Dock-2, researchers determined that neferine has a high binding affinity with protein receptors that are pivotal in several biological processes. In conclusion, the study provides strong evidence that pretreatment with neferine protects rats from ISO-induced heart damage.
This study will enroll adult participants, 18-60 years of age, with moderate-to-severe atopic dermatitis (AD) and a positive Staphylococcus aureus (S. aureus) colonized lesion (at least 15 cm\^2 in size) on the upper extremities.

Participants who are eligible based on their positive Staph culture results will be randomized to one of two treatments: Targeted Microbiome Transplant Lotion (TMT) or Placebo (2:1 randomization). One lesional site measuring at least 15 cm\^2 and one non-lesional site of equal size will be identified on the participant's ventral upper extremities as the target swabbing areas. These sites will be photographed and marked for swabbing for reference at the participant's future visits. Participants will be instructed to apply investigational product with gloved hands to their ventral upper extremities bilaterally from the wrist to the upper humerus, which will include the identified lesional and non-lesional swabbing sites twice a day for 1 week starting on Day 0. Participants will return to clinic on Day 4 for the assessment of adverse events, the collection of skin swabs from the identified target sites, and to obtain additional investigational product and gloves. Participants will complete an additional clinic visit on Day 7 to correspond with the end of their 1 week treatment. During this visit, participants will be assessed for AEs and provide skin swab samples. All unused product and empty packets will be returned during the Day 4 and Day 7 visits. Three additional clinic visits on Days 8, 9, and 11 will be scheduled for additional skin swabs to assess the safety and the stability of the microbiome transplant and time to recurrence of Staph colonization. Participants will be followed through Day 38 to assess for safety and disease status.
Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
The invention discloses a composite enzyme and a preparation method of the composite enzyme, which relates to the field of a pharmaceutical preparation. The composite enzyme is composed of a liquid matrix and an additive. The liquid matrix comprises water and bacterial liquid. The bacterial liquid comprises one or more of Monascaceae, Candida utilis and Lactobacillus plantarum. The additive comprises one or more of sea buckthorn, common stonecrop herb, astragalus, Chinese wolfberry, Chinese yam, safflower, ginseng, bean and a sweetener. The bean is black bean or jumby bean. The matrix also comprises bone paste prepared by pulverizing bone powder of livestock. The composite enzyme provided by the invention has the advantages of improving immunity, and lowering blood pressure, blood glucose and blood lipid.
The individuals in this group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum. Instead, they will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
Includes participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
This is a two-arm, randomized, double-blind and double-dummy, placebo controlled study to evaluate the efficacy, tolerability, and safety of vigabatrin versus rapamycin as a preventive treatment in infants with TSC. The study consists of 3 phases for each patient: screening, core blinded phase, and open-label follow-up phase. Patients who meet the eligibility criteria will be randomized to receive vigabatrin or rapamycin. The randomization ratio is 1:1. Randomization will be stratified by the sex and the presence of epileptiform activity on baseline videoEEG (video electroencephalography) recording (yes versus no). Approximately 60 infants are planned to be enrolled in the study.
1. The use of lactadherin or a variant thereof, for the preparation of a composition for regulating the immune response. 2. The use according to claim 1, for the inhibition of the cross-priming of antigens. 3. The use according to claim 2, of a variant of lactadherin lacking a functional phospolipid binding site and/or a functional integrin binding site. 4. The use according to claim 1, for the stimulation of the phagocytosis of antigens by dendritic cells. 5. The use according to claim 1, for the stimulation of the cross-priming of antigens. 6. The use of lactadherin or a variant thereof, for the preparation of a composition for the delivery of a molecule to a dendritic cell. 7. The use according to any one of the preceding claims, wherein the lactadherin or variant thereof is human lactadherin or a variant thereof. 8. An immunogenic composition comprising lactadherin or a variant thereof in association with an antigen or cytokine. 9. The composition according to claim 8, wherein said antigen or cytokine is covalently associated to the lactadherin or variant thereof. 10. The composition according to claim 8, comprising a liposome, wherein said liposome comprises lactadherin or a variant thereof covalently associated with in association with antigen or cytokine. 11. An immunogenic composition comprising lactadherin or a variant thereof in association with an antigen. 12. The composition according to claim 11, wherein antigen is protein, polypeptide, peptide, virus or bacteria. 13. A chimeric protein comprising lactadherin or a variant thereof fused to immunogen or immunostimulant polypeptide. 14. A nucleic acid encoding a protein according to claim 13. 15. A liposome comprising a recombinant lactadherin or variant thereof. 16. An immunogenic composition comprising a chimeric protein according to claim 13 or a liposome according to Claim 15. 17. A recombinant virus expressing lactadherin as a surface molecule. 18. A recombinant cell expressing lactadherin as a surface molecule.